Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will again participate in Europe’s flagship life sciences partnering conference, BIO-Europe 2023, this year in Munich.
enGenes team will take part in the event’s extensive networking platform, to promote the company’s advanced proprietary high yield expression technologies.
Leading edge protein expression
The enGenes team will be ready to communicate the technological advantages of its platforms such as the E. coli-based enGenes-eXpress™ growth decoupled expression system and its related suite of solutions.
These include -eXtra™ for extracellular secretion of recombinant proteins, -eXpand™ for expansion of genetic code and incorporation of non-canonical amino acids, -eXcite™ for continuous production of biomolecules, and -eXcess™ for pDNA upstream and downstream processing and growth-decoupled pDNA production.
enGenes will also be able to highlight its offer of optimized protein expression using the -exchange™ technology, an antibiotic resistance marker-free expression system.
Array of service offers
It will also be seeking partners for its other services, such as cloning and vector optimization, host cell engineering, high-throughput screening of expression clones, development of downstream processing routes, scale-up and tech transfer.
“We are delighted to be returning to Bio-Europe, which provides superb opportunities to strengthen ties with existing partners and explore new collaboration opportunities,” said Dr. Juergen Mairhofer, CEO and co-founder of the company.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes- eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
About BIO-Europe 2023
BIO-Europe® is a premier partnering conference that annually attracts an international “who’s who” of decision makers from Europe’s biotech, pharma and investment communities for high caliber networking.
The three-day 2023 event opens November 6 at the Messe München Trade Fair Center in Munich, with a further digital partnering event scheduled for November 14-15.
Featuring a sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.
The event is expected to involve up to 5,500 potential partners, with a conference agenda structured around the headline themes of Partnering and Investment Trends, Therapeutics Insights, and Ecosystem Innovation. The program also features more than 20 workshops and panels, with thousands of licensing opportunities posted.
The event is organized by Informa Connect with more information at: https://informaconnect.com/bioeurope